Comparative Pharmacology
Head-to-head clinical analysis: ANUSOL HC versus BETADERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANUSOL HC versus BETADERM.
ANUSOL HC vs BETADERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone, a corticosteroid, binds to glucocorticoid receptors, inhibiting phospholipase A2 activity and reducing prostaglandin and leukotriene synthesis. It also suppresses cytokine production and inflammatory cell migration, leading to decreased edema, erythema, and pruritus in anorectal tissues.
Betamethasone dipropionate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins (lipocortins) and inhibition of arachidonic acid release, thereby reducing prostaglandin and leukotriene synthesis.
Apply a thin layer to the affected area rectally 2 to 4 times daily, or after each bowel movement, for up to 7 days. Each application should not exceed 1 gram.
Topical: Apply a thin film to affected skin twice daily; maximum 100 g per week for adults.
None Documented
None Documented
Terminal elimination half-life of hydrocortisone is approximately 1.5-2 hours (range 1-3 h) in adults; clinical effect outlasts half-life due to intracellular receptor-mediated action.
Terminal elimination half-life is approximately 18-36 hours (mean ~24 hours) following topical application; systemic half-life after oral administration is similar, reflecting prolonged tissue retention.
Renal (primarily as metabolites) >80%; fecal ~15%; <2% unchanged in urine due to extensive hepatic metabolism. Biliary excretion is negligible.
Renal excretion of metabolites (mainly as glucuronide and sulfate conjugates) accounts for approximately 60-70% of elimination; fecal/biliary excretion accounts for 30-40%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid